1 2 3
API
Dominant pharmaceutical intermediates
Febuxostat intermediate
Tedezolamine phosphate intermediate
Other intermediates
Search
 
Your location: Home > News
The State Food and Drug Administration approved the listing of Yinqiao Qingre tablet, an innovative
 
 

According to the website of the State Drug Administration, recently, the State Drug Administration approved the listing registration application of Yinqiao Qingre tablets. Jiangsu Kangyuan Pharmaceutical Co., Ltd. is the holder of the marketing license of this variety of drugs.


This product is an innovative traditional Chinese medicine developed on the basis of clinical experience. A multicenter, randomized, double-blind, placebo / positive drug parallel control clinical trial has been carried out. The results show that it can be used for the treatment of exogenous wind heat common cold.


The listing of the new traditional Chinese medicine provides a new treatment option for patients with common cold.


[The information has been viewed Times]
 

Close the window

www.chuangyepharma.com zwl13325129676@163.com (0)13325129676 Manager Zhang

Copyright © 2020 www.chuangyepharma.com Shandong Chuangye Pharmaceutical Technology Co., Ltd.
Room 249, Building 11, Haina City Headquarters Park, No. 555 Meili Road, Huaiyin District, Jinan City, Shandong Province